Physician profile
Vikram Sumbly
NPI 1437772043
$1,416.29
in general payments reported to CMS, 2019-2025
17 companies · $926 in 2025
The $926 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.83 · 2024: $471 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033 · Education: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.36 |
| Education | $382.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $299.73 | 2025 | Rybrevant, Carvykti, Erleada |
| Daiichi Sankyo INC. | $216.46 | 2024-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $208.11 | 2024-2025 | Opdivo, Reblozyl |
| Novartis Pharmaceuticals Corporation | $104.75 | 2024-2025 | |
| Glaxosmithkline, LLC. | $97.83 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Sanofi-Aventis U.S. LLC | $93.95 | 2024 | |
| Amgen INC. | $88.64 | 2024 | Lumakras |
| Genzyme Corporation | $61.31 | 2024 | |
| Eisai INC. | $53.54 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $38.78 | 2025 | Enhertu |
| Pharmacosmos Therapeutics INC. | $36.56 | 2024-2025 | Monoferric |
| Taiho Oncology, INC. | $31.42 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $18.18 | 2025 | Libtayo |
| Merck Sharp & Dohme LLC | $17.55 | 2024 | Keytruda, Lynparza |
| Abbvie INC. | $17.17 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $17.14 | 2025 | Jakafi |
| Celgene Corporation | $15.17 | 2025 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Sumbly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.